The HNRNPLL Knockout A-549 Polyclonal Cells represent a polyclonal population of A-549 cells modified by CRISPR/Cas9-mediated gene disruption at the HNRNPLL locus. This heterogeneous pool of edited cells serves as a loss-of-function model for studying the regulatory roles of the heterogeneous nuclear ribonucleoprotein L-like (HNRNPLL) protein. Unlike clonal cell lines, the polyclonal format preserves genetic diversity while ensuring robust representation of knockout genotypes, facilitating pooled functional studies in a lung adenocarcinoma background.
The parental A-549 cell line is an adherent epithelial model derived from a 58-year-old male patient with lung adenocarcinoma. Widely employed as a representative system for non-small cell lung cancer (NSCLC), A-549 cells are a standard choice for cancer biology research, drug discovery, and toxicology screening. Their reproducible growth characteristics and well-characterized genomic landscape make them an ideal host for dissecting gene function in lung cancer pathophysiology.
HNRNPLL encodes an RNA-binding protein that functions as a critical regulator of alternative pre-mRNA splicing. Activated downstream of T-cell receptor and IL-2 signaling pathways, HNRNPLL modulates the splicing of multiple target transcripts, including CD45 (PTPRC), CD44, and FAS. It forms functional interactions with spliceosomal components and other RNA-binding proteins such as HNRNPL and SRSF1. Through these interactions, HNRNPLL influences the expression of isoform variants linked to apoptosis, as evidenced by its effects on FAS splicing and the consequent regulation of caspase-8-mediated cell death. In lung adenocarcinoma cells, HNRNPLL-dependent splicing events are thought to impact proliferation and survival pathways.
Disruption of HNRNPLL in A-549 cells is predicted to alter splice isoform profiles of key genes involved in apoptosis and cell signaling, potentially rendering the cells more sensitive or resistant to certain therapeutic agents. This polyclonal knockout model enables the investigation of HNRNPLL’s role in maintaining the malignant phenotype of NSCLC. It also provides a platform to explore the functional consequences of aberrant splicing in lung cancer and to evaluate the therapeutic potential of splicing modulators in a disease-relevant context. The model is particularly suited to study how HNRNPLL loss influences cell viability, migration, and drug response.
Researchers can apply this knockout product in a range of experimental assays to characterize HNRNPLL function. RT-qPCR and RNA sequencing can be used to identify and quantify splicing alterations of target genes such as CD44 and FAS. Western blotting confirms HNRNPLL protein depletion, while MTT and Annexin V assays assess cell viability and apoptosis. Transwell migration assays evaluate metastatic potential, and drug sensitivity testing with chemotherapeutics or splicing inhibitors reveals functional dependencies. The polyclonal nature of the cells supports pooled screening approaches and transcriptomic analyses that capture a broad spectrum of editing outcomes. For detailed protocols or to inquire about custom options, please contact Ascent Research.
